Ulysses Management’s Pacific Biosciences PACB Stock Holding History

Ulysses Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-222,910	Closed	-$791K	–	56
2018 Q2	$791K	Hold	222,910	–	–	0.07%	47
2018 Q1	$457K	Hold	222,910	–	–	0.04%	55
2017 Q4	$588K	Sell	222,910 -1,917	-0.9%	-$6.71K	0.06%	50
2017 Q3	$1.18M	Sell	224,827 -33,083	-13%	-$142K	0.13%	48
2017 Q2	$918K	Hold	257,910	–	–	0.11%	52
2017 Q1	$1.33M	Buy	+257,910	New	+$1.26M	0.21%	38

Other funds holding PACB

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Ulysses Management's PACB Position: Q3 2018 in Review

Ulysses Management sold out of Pacific Biosciences (PACB) in Q3 2018, closing a stake of 222,910 shares — an estimated $791K sold.

Ulysses Management first reported a position in PACB in Q1 2017 and held it in 6 quarters. The position peaked at $1.33M in Q1 2017. 118 funds tracked by Wall St. Rank hold PACB as of Q3 2018.

Ulysses Management reported no remaining Pacific Biosciences position as of Q3 2018 after selling out during the quarter.
Ulysses Management sold 222,910 Pacific Biosciences shares in Q3 2018, an estimated $791K.
Ulysses Management first reported a position in Pacific Biosciences in Q1 2017 and held it in 6 quarters.
Ulysses Management's Pacific Biosciences position peaked at $1.33M in Q1 2017.
118 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2018.

Based on Ulysses Management's 13F filing for Q3 2018, filed 14 Nov 2018.